Ironwood Pharmaceuticals Inc - Class A logo

IRWD

Ironwood Pharmaceuticals Inc - Class A

$11.74

Earnings Summary

Revenue
$97.23Mn
Net Profits
$37.08Mn
Net Profit Margins
38.14%
PE Ratio
12.01

Highlights

Revenue:

Ironwood Pharmaceuticals Inc - Class A’s revenue fell -6.54% since last year same period to $97.23Mn in the Q2 2022. On a quarterly growth basis, Ironwood Pharmaceuticals Inc - Class A has generated -0.31% fall in its revenue since last 3-months.

Net Profits:

Ironwood Pharmaceuticals Inc - Class A’s net profit fell -90.52% since last year same period to $37.08Mn in the Q2 2022. On a quarterly growth basis, Ironwood Pharmaceuticals Inc - Class A has generated -4.44% fall in its net profits since last 3-months.

Net Profit Margins:

Ironwood Pharmaceuticals Inc - Class A’s net profit margin fell -89.86% since last year same period to 38.14% in the Q2 2022. On a quarterly growth basis, Ironwood Pharmaceuticals Inc - Class A has generated -4.14% fall in its net profit margins since last 3-months.

PE Ratio:

Ironwood Pharmaceuticals Inc - Class A’s price-to-earnings ratio after this Q2 2022 earnings stands at 12.01.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Ironwood Pharmaceuticals Inc - Class A post its latest quarter earnings

EPS Estimate Current Quarter
0.3
EPS Estimate Current Year
0.3

Highlights

EPS Estimate Current Quarter:

Ironwood Pharmaceuticals Inc - Class A’s earning per share (EPS) estimates for the current quarter stand at 0.3 - a 15.38% jump from last quarter’s estimates.

EPS Estimate Current Year:

Ironwood Pharmaceuticals Inc - Class A’s earning per share (EPS) estimates for the current year stand at 0.3.

Key Ratios

Key ratios of the Ironwood Pharmaceuticals Inc - Class A post its Q2 2022 earnings

Return on Assets (ROA)
0.15
Return on Equity (ROE)
0.33
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ironwood Pharmaceuticals Inc - Class A’s return on assets (ROA) stands at 0.15.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ironwood Pharmaceuticals Inc - Class A’s return on equity (ROE) stands at 0.33.

Dividend Per Share (DPS):

Ironwood Pharmaceuticals Inc - Class A declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
0.26
0.21
-19.23%

Company Information

Ironwood Pharmaceuticals is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. The company discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

Organisation
Ironwood Pharmaceuticals Inc - Class A
Headquarters
Boston, Massachusetts, US
Employees
232
Industry
Health Technology
CEO
Mark Mallon